PremiumThe FlyVera Therapeutics drops 30% after rival Otsuka presents Phase 3 data Buy Rating for Vera Therapeutics: Promising Atacicept Data and Market Potential in IgAN Treatment 3 Best Stocks to Buy Now, 6/4/2025, According to Top Analysts PremiumThe FlyVera Therapeutics price target raised to $65 from $55 at Scotiabank Buy Rating for Vera Therapeutics: Promising Potential of Atacicept in IgA Nephropathy Treatment Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment PremiumMarket News3 Best Stocks to Buy Now, 5/26/2025, According to Top Analysts Buy Rating for Vera Therapeutics Driven by Promising Phase III Results and Market Potential Vera Therapeutics Holds 2025 Annual Stockholder Meeting 
